(Q33345228)

English

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Geneviève Chêne

8

object named as

Geneviève Chêne

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

François Clavel

6

object named as

François Clavel

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laurence Morand-Joubert

2

object named as

Laurence Morand-Joubert

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anne-Marie Taburet

10

object named as

Anne-Marie Taburet

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

object named as

Gilles Raguin

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clotilde Le Tiec

5

object named as

Clotilde Le Tiec

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gwendoline Poizat

3

object named as

Gwendoline Poizat

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Aurélie Barrail-Tran

1

object named as

Aurélie Barrail-Tran

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pierre-Marie Girard

9

object named as

Pierre-Marie Girard

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Elisabeth Dam

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Puzzle-1 (ANRS 104) Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

19 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1642-1646

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Role of the inhibitory quotient in HIV therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Protein binding in antiretroviral therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

21 June 2018

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Lopinavir protein binding in vivo through the 12-hour dosing interval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346619

31 October 2018

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285478

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285478

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285478

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.01314-07

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33345228&oldid=1985472221"